Outcome | Active SMT (n = 40) | Placebo SMT (n = 41) | Overall (95% CI) |
---|---|---|---|
Primary outcome | |||
Bang BI of participants—study visit 1a | 0.50 (0.26 to 0.74) | 0.37 (0.10 to 0.63) | Sum BI, 0.87 (0.51 to 1.23) |
Bang BI of participants—study visit 2a | 0.36 (0.08 to 0.64) | 0.29 (0.01 to 0.57) | Sum BI, 0.65 (0.26 to 1.04) |
Secondary outcomes | |||
James BI of participants—study visit 1b | 0.35 (0.24 to 0.45) | ||
James BI of participants—study visit 2b | 0.37 (0.27 to 0.48) | ||
Bang BI of outcome assessors—study visit 1c | 0.08 (− 0.05 to 0.20) | − 0.12 (− 0.24 to − 0.00) | Sum BI, − 0.04 (− 0.22 to 0.14) |
Bang BI of outcome assessors—study visit 2c | 0.03 (− 0.11 to 0.16) | − 0.07 (− 0.21 to 0.07) | Sum BI, − 0.04 (− 0.23 to 0.15) |
James BI of outcome assessors—study visit 1c | 0.93 (0.87 to 0.98) | ||
James BI of outcome assessors —study visit 2c | 0.91 (0.85 to 0.97) |
Other participant outcomes | Active SMT (n = 40) | Placebo SMT (n = 41) | Effect (95% CI) |
---|---|---|---|
Credibility—study visit 2, mean (SD)d | 6.40 (1.76) | 4.91 (2.50) | MD, 1.49 (0.55 to 2.43) |
Expectancy—study visit 2, mean (SD)e | 6.17 (1.65) | 4.84 (2.54) | MD, 1.33 (0.40 to 2.26) |
Credibility/Expectancy—study visit 2, mean (SD)f | 6.29 (1.66) | 4.87 (2.49) | MD, 1.42 (0.50 to 2.34) |
Change in ROM—degrees, mean (SD)g | |||
Flexion | − 2.72 (11.65) | 0.07 (10.36) | MD, − 2.79 (− 7.63 to 2.05) |
Extension | − 0.03 (6.39) | 0.73 (8.57) | MD, − 0.76 (− 4.06 to 2.54) |
Total | − 2.74 (13.98) | 0.80 (14.99) | MD, − 3.54 (− 9.89 to 2.81) |